Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 78 results
Filters: First Letter Of Title is P  [Clear All Filters]
Found 78 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

P

Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT. "Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population." PLoS ONE. 2015;10(6):e0129519.
Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. "Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2007;44(3):268-77.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
Kalayjian RC, Machekano RN, Rizk N, et al. "Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy." J. Infect. Dis.. 2010;201(12):1796-805.
Robertson KR, Smurzynski M, Parsons TD, et al. "The prevalence and incidence of neurocognitive impairment in the HAART era." AIDS. 2007;21(14):1915-21.
Fife KH, Wu JW, Squires KE, D Watts H, Andersen JW, Brown DR. "Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2009;51(3):274-82.
Shivakoti R, Christian P, Yang W-T, et al. "Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults." Clin Nutr. 2016;35(1):183-9.
Dykes C, A Mukherjee L, Bosch RJ, Connick E, Volberding PA, Demeter LM. "Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371." J. Acquir. Immune Defic. Syndr.. 2010;55(1):132-4.
Cohen MS, Chen YQ, McCauley M, et al. "Prevention of HIV-1 infection with early antiretroviral therapy." N. Engl. J. Med.. 2011;365(6):493-505.
Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. "Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084." AIDS Patient Care STDS. 2008;22(1):29-40.
Currier JS, Kendall MA, W Henry K, et al. "Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults." AIDS. 2007;21(9):1137-45.
Stein JH, Ribaudo HJ, Hodis HN, et al. "A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness." AIDS. 2015;29(14):1775-83.
Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. "Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa." AIDS Res Treat. 2011;2011:769627.
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Gupta SK, Komarow L, Gulick RM, et al. "Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects." J. Infect. Dis.. 2009;200(4):614-8.
Kalayjian RC, Wu K, Evans S, et al. "Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2014;67(1):30-5.
Paul RH, Yiannoutsos CT, Miller EN, et al. "Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity." J Neuropsychiatry Clin Neurosci. 2007;19(3):283-92.
Safren SA, Biello KB, Smeaton L, et al. "Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial." PLoS ONE. 2014;9(8):e104178.

Pages